Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

ClinicalTrials.gov ID: NCT05620823

Public ClinicalTrials.gov record NCT05620823. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

Study identification

NCT ID
NCT05620823
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Incyte Corporation
Industry
Enrollment
608 participants

Conditions and interventions

Interventions

  • Povorcitinib Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 18, 2022
Primary completion
Feb 2, 2025
Completion
Dec 22, 2025
Last update posted
Feb 9, 2026

2022 – 2025

United States locations

U.S. sites
37
U.S. states
19
U.S. cities
35
Facility City State ZIP Site status
Investigative Site US303 Phoenix Arizona 85006
Investigative Site US335 Arkansas City Arkansas 72758
Investigative Site US307 Fort Smith Arkansas 72916
Investigative Site US315 Laguna Niguel California 92677
Investigative Site US326 Los Angeles California 90045
Investigative Site US323 San Francisco California 94118
Investigative Site US306 Boca Raton Florida 33486
Investigative Site US320 Boca Raton Florida 33486
Investigative Site US317 Hialeah Florida 33012-3618
Investigative Site US338 Margate Florida 33063
Investigative Site US321 North Miami Beach Florida 33162-4708
Investigative Site US316 Orlando Florida 32819
Investigative Site US328 Tampa Florida 33612
Investigative Site US336 Tampa Florida 33613
Investigative Site US311 Marietta Georgia 30060-1047
Investigative Site US327 Chicago Illinois 60612
Investigative Site US319 Skokie Illinois 60077
Investigative Site US337 Indianapolis Indiana 46250
Investigative Site US341 Bowling Green Kentucky 42103
Investigative Site US334 Metairie Louisiana 70006
Investigative Site US333 Baltimore Maryland 21287
Investigative Site US325 Columbia Maryland 21045
Investigative Site US318 Beverly Massachusetts 01915
Investigative Site US304 Boston Massachusetts 02215
Investigative Site US310 Brighton Massachusetts 02135
Investigative Site US302 St Louis Missouri 63110
Investigative Site US331 Albuquerque New Mexico 87102
Investigative Site US324 Kew Gardens New York 11415
Investigative Site US339 Bexley Ohio 43209
Investigative Site US330 Boardman Ohio 44512
Investigative Site US314 Cincinnati Ohio 45219
Investigative Site US312 Cleveland Ohio 44106
Investigative Site US301 Portland Oregon 97223
Investigative Site US340 Bellaire Texas 77401
Investigative Site US300 Plano Texas 75025
Investigative Site US313 Norfolk Virginia 23502
Investigative Site US308 Spokane Washington 99202

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05620823, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 9, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05620823 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →